Evan Lockwood Rachlin reported an Iambic Therapeutics share purchase

What did the Form 4 report?

Rachlin reported an open-market purchase of 718,750 Iambic Therapeutics (IAM) shares at $16.00 each, for about $11.5M. The transaction date was Oct 16, 2026, and the SEC Form 4 was filed on Oct 19, 2026, 3 days later.

The filing states that the shares are held indirectly. The reported holding after the purchase was 2,588,248 shares, an increase of about 38.4% over the estimated holding before.

What other transaction did Rachlin report?

Rachlin's filings also report an exercise or conversion of derivative securities dated Oct 16, 2026. The transaction code is M or C, and the filing describes 411K IAM derivative securities exercised or converted.

A Form 4 reports a transaction but does not state why it was made. Some purchases and sales follow trading windows or pre-arranged plans; OQRO notes a plan only when a filing footnote says so. The filing does not state which circumstances apply here.

How does the purchase compare with prior filings?

OQRO holds no other open-market purchases by Rachlin in the 365 days to Oct 19, 2026. OQRO does not hold enough history to say whether this is a first purchase. Only 0 of Rachlin's disclosed purchases have had 90 days since they were reported, too few for OQRO to show a result.

OQRO's Iambic Therapeutics insider records begin on Oct 17, 2026, so there is not enough history for a 12-month baseline. In the 90 days to Oct 19, 2026, 0 other open-market purchases, about $0 by 0 insiders, were filed. These comparisons use only the filings OQRO holds. See Iambic Therapeutics on OQRO.

What was happening around the transaction date?

Iambic Therapeutics filed a Form 8-K of Oct 16, 2026, with Items 5.03 and 7.01 on the same day. OQRO classifies the filing as reporting a change to bylaws, charter or fiscal year, and sharing information with investors. An 8-K item states what the company reported, not what it means for the share price.

Finnhub listed the headline “U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings” from SeekingAlpha, Oct 17, 2026, and “Iambic Announces Pricing of Initial Public Offering” from Yahoo, Oct 14, 2026. The headlines are listed as published by the outlets; OQRO has not checked them or summarized the articles.

IAM closed at $23.81 on Oct 16, 2026, the last session on or before the trade date. From Oct 15, 2026 to Oct 16, 2026, the close moved from $18.91 to $23.81, a change of +25.9%. The filing does not explain the price move, and other news can move a price.

What this does not tell you?

The Form 4 does not state why Rachlin made the purchase or whether a trading window, option exercise, tax bill or pre-arranged plan applied. General background is that many companies let insiders trade only in a window that opens after results, and a sale can also follow an option exercise, a tax bill or a pre-arranged plan. The filing does not state which, if any, applies here.

The filing does not explain share-price moves. OQRO's comparisons use only the filings it holds; available records are not enough for a 12-month baseline or a result based on 90 days after the reported purchases. This describes public filings and is not investment advice.